Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

(MENAFN- GlobeNewsWire - Nasdaq) Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...